Pipeline

Our pipeline of immune-modulating, clinical-stage product candidates are based on strong biologic rationale or validated mechanisms, target underserved conditions and offer the potential for differentiation.

Program & Target	Therapeutic Area	Preclinical	Rights
Rilonacept* IL-1α & IL-1β	Recurrent Pericarditis	End Phase 3	Worldwide (excluding the Middle East and North Africa)
Mavrilimumab** GM-CSFRα	Giant Cell Arteritis	Phase 2	Worldwide
Mavrilimumab** GM-CSFRα	COVID-19 Pneumonia & Hyperinflammation	Phase 2	Worldwide
Vixarelimab*** OSMRβ	Prurigo Nodularis	Phase 2	Worldwide
Vixarelimab*** OSMRβ	Diseases Characterized by Chronic Pruritus	Phase 2	Worldwide
KPL-404 CD40	T-Cell Dependent, B-Cell–Mediated Indications	Phase 1	Worldwide

*The FDA accepted the sBLA with priority review and assigned a PDUFA goal date of March 21, 2021; The FDA granted Breakthrough Therapy designation to rilonacept for recurrent pericarditis in 2019 and Orphan Drug designation to rilonacept for pericarditis in 2020.
** The FDA granted Orphan Drug designation to mavrilimumab for giant cell arteritis in 2020.
***The FDA granted Breakthrough Therapy designation to vixarelimab for pruritus associated with prurigo nodularis in 2020.

Every Second Counts!